Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysisBMJ 2018; 361 doi: https://doi.org/10.1136/bmj.k2295 (Published 23 May 2018) Cite this as: BMJ 2018;361:k2295
The prices quoted for the threshold analysis at the end of the cost effectiveness results section and in the table of Appendix 2 of this Research paper (BMJ 2017;359:j5058, doi:10.1136/bmj.j5058) are incorrect. The authors found that, to be more cost effective than apixaban, dabigatran’s price would have to reduce from an annual cost of £801.76 to £487.86, edoxaban would have to reduce from £801.76 to £222.93, and rivaroxaban would have to reduce from £766.52 to £201.47. A substantial discount is therefore necessary for these direct acting oral anticoagulants to become more cost effective than apixaban, but negative prices are not necessary.
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.